Skip to main content
SpringerLink
Log in

Safety Assessment of Marketed Medicines (SAMM) studies: problems addressed but problems raised?

  • Commentary
  • Published:
International Journal of Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1

References

  1. Fung M, Thornton A, Mybeck K, Wu JH-H, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets, 1960–1999. Drug Inform J 2001; 35:293–317.

    Article  Google Scholar 

  2. Joint Committee of the ABPI, BMA, CSM and RCGP. Guidelines on postmarketing surveillance. BMJ 1988; 296:399–400.

    Article  Google Scholar 

  3. Waller PC, Wood SM, Langman MJ, Breckenridge AM, Rawlins MD. Review of company post-marketing surveillance studies. BMJ 1992; 304:1470–1472.

    Article  PubMed  CAS  Google Scholar 

  4. Association of the British Pharmaceutical Industry. Guidelines for companysponsored safety assessment of marketed medicines (SAMM). In: ABPI compendium of data sheets and summaries of product characteristics. London: Datapharm Publications; 1996.

    Google Scholar 

  5. Pocock SJ. Clinical trials — a practical approach. Chichester: John Wiley; 1983. pp. 50–65.

    Google Scholar 

  6. Ayres JG, Frost CD, Holmes WF, Williams DRR, Ward SM. Post-marketing surveillance study of a CFC-free inhaler according to Safety Assessment of Marketed Medicines (SAMM) guidelines. BMJ 1998; 317:926–930.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Birmingham Heartlands Hospital, Birmingham, UK

    Jon G. Ayres

  2. Department of Epidemiology and Population, London School of Hygiene and Tropical Medicine, London, UK

    Chris Frost

  3. Sherrington Park Medical Centre, Nottingham, UK

    William F. Holmes

  4. Division of Public Health and Primary Care Institute of Health Sciences, University of Oxford, Oxford, UK

    Katherine M. Venables

  5. 3M Healthcare Ltd., Loughborough, UK

    Susan M. Ward

Authors
  1. Jon G. Ayres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris Frost
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William F. Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katherine M. Venables
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan M. Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jon G. Ayres.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ayres, J.G., Frost, C., Holmes, W.F. et al. Safety Assessment of Marketed Medicines (SAMM) studies: problems addressed but problems raised?. International Journal of Pharmaceutical Medicine 16, 167–169 (2002). https://doi.org/10.2165/00124363-200208000-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00124363-200208000-00002

Keywords

Search

Navigation